C.N. Owen

UK multicentre real-world data of the use of cyclin-dependent kinase 4/6 inhibitors in metastatic breast cancer

Georgina Gullick, C.N. Owen, William John Watkins, Seamus Cook et autres

Background: Cyclin-dependent kinase 4/6 inhibitors (CDK4/6is) are widely used to treat hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). This study aimed to capture the real-world efficacy and tolerability of CDK 4/6is. Patients and methods: Data …

gb, ca (code pays fourni par la source)

867P The association between polygenic risk of autoimmune disease, progression-free survival (PFS), and pathway-level transcriptomic signatures predictive of anti-PD1 response in melanoma

C.N. Owen, G. Richenberg, V. Gray, A. Nounu et autres

gb (code pays fourni par la source)